A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients.

Intensive Care Med Exp · 2025 · PMC12360993 · PMID 40824474

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

A notable trend was observed in most patients, where H3 plasma levels were increased at the end of infusion and/or T = 10 h, correlating with plasma M6229 levels (Fig. 5 A).

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.